SiteOne Therapeutics Inc., a Bozeman, Montana-based developer of a platform of non-opioid therapeutics for acute and chronic pain, completed a funding round of undisclosed amount.
The round was led by Next Frontier Capital with participation from 2M Companies and current investors Sears Capital Management, Biobrit LLC, Mission Bay Capital and Z Investments. In conjunction with the financing, Will Price, founder and managing partner of Next Frontier Capital, will join SiteOne’s board of directors.
Founded with technology invented at Stanford University and led by Stan E. Abel, chief executive officer, SiteOne Therapeutics is advancing an oral, highly selective inhibitor of voltage-gated sodium ion channel, NaV1.7, for the treatment of moderate to severe pain, which represents a potentially safer and more effective treatment option to replace oral opioid analgesics.
Additional opportunities with the company’s technology include long-acting analgesics, PET imaging diagnostics for pain and other pain indications.
SiteOne owns worldwide development and commercialization rights to its development programs through an exclusive license from Stanford University.